FTFinancial Times·2hBusiness
score+0.60
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Original
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
“Acquisition framed constructively with emphasis on record deal size and positive M&A momentum.”